Literature DB >> 30112779

Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study.

Sinem Ezgi Gulmez1, Ulku Sur Unal2, Régis Lassalle1, Anaïs Chartier1, Adeline Grolleau1, Nicholas Moore1.   

Abstract

PURPOSE: The SALT study found similar per-user risks of acute liver failure (ALF) leading to transplantation (ALFT) between NSAIDs and a threefold higher risk in nonoverdose paracetamol (NOP) users. The objective of EPIHAM was to identify the risks of hospital admission for acute liver injury (ALI) associated with NSAIDs and NOP.
METHODS: Case-population study in the 1/97 sample of the French population claims database. Acute liver injury was identified from hospital discharge summaries, from 2009 to 2013. Exposure for cases was dispensing of NSAID or NOP resulting in exposure within 30 days before admission. Population exposure was the number of patients using the drugs over the study timeframe and total number of DDD dispensed.
RESULTS: Of 63 cases of ALI, 13 had been exposed to NSAIDs and 24 to NOP. Events per million DDD (95% CI) ranged from 0.46 (0.09-1.34) (ketoprofen) to 1.43 (0.04-7.97) (diclofenac combinations), 0.43 (0.23-0.73) all NSAIDs combined, 0.58 (0.37-0.86) for NOP. There was no association with average duration of treatment. Per patient risk ranged from 19.5 (5.31-49.9) (ibuprofen) per million users to 37.2 (19.8-63.6) all NSAIDs combined, 58.0 (37.2-86.3) for NOP. There was a linear relationship between average treatment duration and per-user risk (R2  = 0.51, P < .05 for NSAIDs, R2  = 0.97, P < .01 for NOP).
CONCLUSIONS: Risk of hospital admission for ALI with NSAIDs and NOP was similar and indicative of a dose and duration-related effect (pharmacological) effect. Acute liver injury rates were not predictive of ALFT risk.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  case-population study; drug-exposed hepatotoxicity; drug-induced liver injury (DILI); nonsteroidal anti-inflammatory drugs (NSAIDs); paracetamol (acetaminophen); pharmacoepidemiology

Mesh:

Substances:

Year:  2018        PMID: 30112779     DOI: 10.1002/pds.4640

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  3 in total

1.  Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Authors:  Nicholas Moore; Stéphanie Duret; Adeline Grolleau; Régis Lassalle; Vanessa Barbet; Mai Duong; Nicolas Thurin; Cécile Droz-Perroteau; Sinem Ezgi Gulmez
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

2.  Does Ibuprofen Worsen COVID-19?

Authors:  Nicholas Moore; Bruce Carleton; Patrick Blin; Pauline Bosco-Levy; Cecile Droz
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

Review 3.  Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy.

Authors:  Maurizio Gabrielli; Laura Franza; Alessandra Esperide; Irene Gasparrini; Antonio Gasbarrini; Francesco Franceschi
Journal:  Vaccines (Basel)       Date:  2022-01-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.